DNA Methylation Market is predicted to be US$ 5815.49 Million at a CAGR of 15% by 2033 | FMI Analyst

During the forecast period 2023-2033, the DNA Methylation Market is expected to grow at a value of 15% CAGR, according to Future Market Insights. By the year 2033, the global market for DNA methylation is expected to rise up to a market valuation of US$ 5815.49 Million. Furthermore, the growing prevalence of esophageal adenocarcinoma has contributed to the overall growth. According to the data published by the American Cancer Society (ACS), in 2022, an estimated 20,640 esophageal cancer cases were undiagnosed in the U.S. The chronic disease. resulted in 16,410 deaths.

Growing esophageal cancer cases in the U.S. highlight the urgent need for early intervention measures that can help improve the low survival rates for patients. In October 2022, a research article published by Fred Hutchinson Cancer Center stated that methylated DNA biomarkers could be used for the detection of esophageal adenocarcinoma and high-grade dysplasia.

Request a Sample of this Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-15893

The significant increase in the adoption of epigenetics-based treatment strategies, coupled with the broad nucleic acid-based diagnostic tests & kits commercialization is projected to drive the growth of the market. In May 2022, an article published in PubMed stated that the epigenetics-based treatment strategies are to be used for studying Alzheimer’s disease.

Moreover, Key players operating in the market are taking several initiatives such as new product developments, entering into a strategic alliance, and regional expansion among others. All these factors are positively influencing the demand for DNA methylation market.

Key Takeaways from the Market Study

• By technology, sequencing is expected to possess 35% market share for DNA methylation market in 2023.
• By product, consumables are expected to possess 35% market share for DNA methylation market in 2023.
• By application, clinical research is expected to possess 40% market share for DNA methylation market in 2023.
• By application, diagnostic segment is anticipated to witness the fastest growth in the coming years with a CAGR of 16%.
• By end use, pharmaceutical and biotechnology end-use segment are expected to possess 42% market share for DNA methylation in 2023.
• North America is expected to possess 40% market share for DNA methylation market in 2023.
• Asia Pacific is expected to possess 38% market share for DNA methylation market in 2023.

Inquire Before Buying Research Report: https://www.futuremarketinsights.com/ask-question/rep-gb-15893

“Expenditure on research and development along with government funding is expected to accelerate the growth of DNA methylation market.” comments a Future Market Insights analyst.

Competitive Landscape

Some prominent players in the global DNA methylation market include New England Biolabs, Sysmex Corporation, Abcam plc., F. Hoffmann-La Roche Ltd., Diagenode Diagnostics S.A., Thermo-Fisher Scientific Inc., Agilent Technologies Inc., BioRad Laboratories Inc., Exact Sciences Corporation, QIAGEN N.V., Active Motif, Inc., Illumina Inc.,EpiGentek Group Inc., Pacific Biosciences Inc., New England Biolabs Inc., Merck KGaA, Zymo Research Corporation, PerkinElmer Inc.

• In May 2022, Oxford Nanopore announced integrating Remora, a technique that offers accurate and real-time epigenetic insights with nanopore sequencing software. This would further offer simple access to accurate whole genome methylation detection.
• In June 2020, Base Genomics announced of advancing and developing its DNA methylation technology. the aim is to sequence a large amount of epigenetic data from a blood test which could revolutionize the preventative medicine arena.

Get Your Report Customize, Visit: https://www.futuremarketinsights.com/customization-available/rep-gb-15893

Key Segments Profiled in the DNA Methylation Industry Survey

Technology:

• Polymerase Chain Reaction (PCR)
• Microarray
• Sequencing
• Others

Product:

• Consumables
• Kits & Reagents
• Enzymes
• Instruments & Software

Application:

• Gene Therapy
• Clinical Research
• Diagnostics
• Others

End-use:

• Hospital & Diagnostic Laboratories
• Pharmaceutical & Biotechnology Companies
• Research & Academia

About Future Market Insights (FMI) 

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs